Clinical Trial Update: T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial of a NY-ESO-1–targeted T cell receptor therapy in NY-ESO-1 expressing metastatic melanoma was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• NY-ESO-1-targeted T cell receptor therapy

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Cancer, Metastatic Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2016-05-18